Page 12 - Dror Bashan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA USA - English Share this article Share this article CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an internat...

Published: Apr 28, 2021 By Mark Terry Protalix Biotherapeutics and Chiesi Global Rare Diseases  announcedthe U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for their Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for adults with Fabry disease. The application was for accelerated approval. The companies indicated they are studying the CRL to determine the best way to understand the problems and what course of action they might take. Fabry disease is an X-linked inherited disorder. It is caused by insufficient activity of the...

Share this article Share this article CARMIEL, Israel, March 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced today announced that the Company's management will participate and present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, a virtual conference taking place March 9–10, 2021. Dror Bashan, ...

Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds USA - English Company, with its Commercialization Partner, Chiesi, poised to commercialize PRX-102 Additional data and milestones expected throughout 2021 News provided by Share this article Share this article CARMIEL, Israel, Feb. 18, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based pro...

Published: Dec 30, 2020 By Alex Keown Shares of Protalix Biotherapeutics were up nearly 7% in premarket trading after the company announced its Phase III BRIDGE study met key objectives in treating Fabry Disease. The announcement followed previous topline data from the study released in May. The study assessed PRX-102 (pegunigalsidase alfa), a plant cell-expressed recombinant, PEGylated, cross-linked α-galactosidase-A product candidate in Fabry patients who switched from treatment with agalsidase alfa. After the switch from agalsidase alfa to PRX-102, researchers noted substantia...